Drugs / ACCS100
ACCS100
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02188953 | Aug → Sep 2014 | aflatoxicosis | Kenya Medical Research Institute | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01677195 Comparator | Sep 2012 → Aug 2014 | — | Texas Enterosorbents Incorporated | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACCS100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01677195 ↗ |
| Known as | Air Classified Calcium Silicate | “Air Classified Calcium Silicate” NCT02188953 ↗ |
| Known as | Hydrated Sodium Calcium Aluminosilicate | “This study involves the use of an investigational drug called Hydrated Sodium Calcium Aluminosilicate (ACCS100).” NCT01677195 ↗ |
| Modality | Other / unclassified | “The primary purpose of the study is to evaluate the effectiveness of a naturally occurring clay substance (ACCS100)” NCT01677195 ↗ |
| Route | Oral | “by Ingestion of ACCS100 Capsules” NCT01677195 ↗ |